^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
RG6232
i
Other names: RG6232, RO7293583
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Roche
Drug class:
CD3 agonist, TYRP1 inhibitor
Related drugs:
1m
Phase 1, first-in-human study of TYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager, in metastatic melanoma: active drug monitoring to assess the impact of immune response on drug exposure. (PubMed, Front Oncol)
This study provides important insights into how the use of active drug PK assays, coupled with mechanistic follow-up, can inform and enable ongoing benefit/risk assessment for individuals participating in FIH dose-escalation trials. Translational studies that lead to a better understanding of the underlying biology of cognate T- and B-cell interactions, ultimately resulting in ADA development to novel biotherapeutics, are needed.
P1 data • Journal • Metastases
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • TYRP1 (Tyrosinase Related Protein 1)
|
RG6232
over1year
A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas (clinicaltrials.gov)
P1, N=20, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed | Trial completion date: Jan 2023 --> Jul 2022 | Trial primary completion date: Jan 2023 --> Jul 2022
Trial completion • Trial completion date • Trial primary completion date • Metastases
|
BRAF (B-raf proto-oncogene) • TYRP1 (Tyrosinase Related Protein 1)
|
Gazyva (obinutuzumab) • Actemra IV (tocilizumab) • RG6232
2years
A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas (clinicaltrials.gov)
P1, N=20, Active, not recruiting, Hoffmann-La Roche | N=310 --> 20
Enrollment change
|
BRAF (B-raf proto-oncogene) • TYRP1 (Tyrosinase Related Protein 1)
|
Gazyva (obinutuzumab) • Actemra IV (tocilizumab) • RG6232
2years
A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas (clinicaltrials.gov)
P1, N=310, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting
Enrollment closed
|
BRAF (B-raf proto-oncogene) • TYRP1 (Tyrosinase Related Protein 1)
|
Gazyva (obinutuzumab) • Actemra IV (tocilizumab) • RG6232
over2years
A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas (clinicaltrials.gov)
P1, N=310, Recruiting, Hoffmann-La Roche | Trial completion date: Sep 2023 --> Jan 2023 | Trial primary completion date: Sep 2023 --> Jan 2023
Trial completion date • Trial primary completion date
|
BRAF (B-raf proto-oncogene) • TYRP1 (Tyrosinase Related Protein 1)
|
Gazyva (obinutuzumab) • Actemra IV (tocilizumab) • RG6232
over3years
A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas (clinicaltrials.gov)
P1, N=310, Recruiting, Hoffmann-La Roche | Not yet recruiting --> Recruiting
Clinical • Enrollment open
|
BRAF (B-raf proto-oncogene) • TYRP1 (Tyrosinase Related Protein 1)
|
Gazyva (obinutuzumab) • Actemra IV (tocilizumab) • RG6232
over3years
A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas (clinicaltrials.gov)
P1, N=310, Not yet recruiting, Hoffmann-La Roche
Clinical • New P1 trial
|
BRAF (B-raf proto-oncogene) • TYRP1 (Tyrosinase Related Protein 1)
|
Gazyva (obinutuzumab) • Actemra IV (tocilizumab) • RG6232
Share via
